NCT03006367View on ClinicalTrials.gov

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 7, 2017

Primary Completion Date

February 26, 2017

Study Completion Date

March 6, 2017

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

NFC-1 100 mg

DRUG

NFC-1 200 mg

DRUG

NFC-1 400 mg

DRUG

NFC-1 800 mg

Trial Locations (3)

32751

Meridien Research, Inc., Maitland

33143

QPS-MRA, LLC (Miami Research Associates), Miami

89128

Center for Psychiatry and Behavioral Medicine, Las Vegas

All Listed Sponsors
lead

Aevi Genomic Medicine, LLC, a Cerecor company

INDUSTRY

NCT03006367 - Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD | Biotech Hunter | Biotech Hunter